Browse by author
Lookup NU author(s): Professor Moein MoghimiORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024 American Chemical Society.In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.
Author(s): Anchordoquy T, Artzi N, Balyasnikova IV, Barenholz Y, La-Beck NM, Brenner JS, Chan WCW, Decuzzi P, Exner AA, Gabizon A, Godin B, Lai SK, Lammers T, Mitchell MJ, Moghimi SM, Muzykantov VR, Peer D, Nguyen J, Popovtzer R, Ricco M, Serkova NJ, Singh R, Schroeder A, Schwendeman AA, Straehla JP, Teesalu T, Tilden S, Simberg D
Publication type: Review
Publication status: Published
Journal: ACS Nano
Year: 2024
Volume: 18
Issue: 22
Pages: 13983–13999
Print publication date: 04/06/2024
Online publication date: 20/05/2024
Acceptance date: 08/05/2024
ISSN (print): 1936-0851
ISSN (electronic): 1936-086X
Publisher: American Chemical Society
URL: https://doi.org/10.1021/acsnano.4c00182
DOI: 10.1021/acsnano.4c00182
